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Context: The focus of care in disorders of sex development (DSD) is often directed on issues related
to sexandgenderdevelopment. Inaddition, themolecular etiology remainsunclear in themajority
of cases.
Objective: To report the range of associated conditions identified in the I-DSD Registry.
Design, Setting&Patients:Anonymizeddatawere extracted from the I-DSDRegistry for diagnosis,
karyotype, sex of rearing, genetic investigations and associated anomalies. If necessary, clarifica-
tion was sought from the reporting clinician.
Results:Of 649 accessible cases, associated conditions occurred in 168 (26%); 103 (61%) cases had
one condition, 31 (18%) two, 20 (12%) three and 14 (8%) four or more. Karyotypes with most
frequently reported associations included 45,X with 6/8 affected cases (75%), 45,X/46,XY with
19/42 cases (45%), 46,XY with 112/460 cases (24%) and 46,XX with 27/121 cases (22%). In the 112
cases of 46,XY DSD, commonest conditions included small for gestational age (SGA) in 26 (23%),
cardiac anomalies in 22 (20%) and CNS disorders in 22 (20%), while in the 27 cases of 46,XX DSD,
skeletal and renal anomalies were commonest at 12 (44%) and 8 (30%), respectively. Of 170 cases
of suspected Androgen Insensitivity Syndrome (AIS), 19 (11%) had reported anomalies and 9 of
these 19 had confirmed androgen receptor mutations.
Conclusions: Over a quarter of cases in the I-DSD Registry have an additional condition. These
associations candirect investigators towards novel genetic etiology andalsohighlight theneed for
more holistic care of the affected person.
Disorders of sexdevelopment (DSD) are a groupof rareconditions that usually present in early infancywith
an abnormality of the external and/or internal reproduc-
tive organs, and commonly arise because of a disorder of
gonadal, adrenal or hormonal function. Although the
overall birth prevalence of conditions associated with
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DSD may be as high as 1 in 300 (1), individual patho-
physiological conditions aremuch rarer, limiting the study
of their etiology and prognosis.
While enormous advances in our knowledge have been
achieved over the last decade, the genetic etiology in most
cases of DSD remains unclear (2, 3). Furthermore, our
understanding of the basis of the genetic modifiers of
monogenic DSD remains in its infancy. Mammalian sex
development, which is already known to be closely linked
to the development of the urological system (4), occurs at
critical stages of embryonic and fetal development. These
windows may also be important for the development of
other organs as illustrated by a number of known condi-
tions associated with DSD (5–7). High-throughput gene
sequencing technology has the potential to identify a num-
ber of attributable genetic variations but understanding
the linkbetween these variations and the clinical condition
may prove to be a challenge. An improved knowledge of
the range of associated conditions that exist in peoplewith
DSDwill not only help with interpreting the results of the
genetic analyses, but will also aid with themanagement of
the affected patient.
Although a link between DSD and associated anoma-
lies is recognized (1), it is generally felt that conditions such
as hypospadias are rarely associated with abnormalities
beyond thegenitourinary (GU) system(8).Given the rarity
ofDSD, it has been difficult to ascertain the frequency and
nature of associated anomalies in these cases. The Con-
sensus Guidelines on DSD published in 2006 stressed the
need for the creation and maintenance of a database in
centers of expertise (9). Such databases do exist in many
regional and national centers and have provided valuable
insights into many aspects of DSD, including epidemiol-
ogy (1), etiology (10, 11), variation of disease expression
(12), initial adjustment of parents to their affected child’s
condition (13), and long-term outcome (14). However, as
these databases and registries lacked uniformity, an inter-
national DSD registry that collects information on cases
with a range of conditions has now been in operation to
overcome these issues (15). We have used this model of
international collaboration to report on the largest cohort
of cases of DSD that has been studied for associated
anomalies.
Patients and Methods
Details of the I-DSD Registry, including its development and
current operation have been previously reported (15, 16) and are
also available from its website (www.i-dsd.org). Briefly, all cli-
nicians belonging to recognized professional medical and scien-
tific societies are eligible to register and report cases. This infor-
mation is requiredwhen the clinician first registers as auserof the
Registry. Users are then approved by the steering committee of
the Registry before they can submit any cases. There are no re-
strictions on the age requirement of the case, with the Registry
servingboth adult andpediatric populations, and there is no time
limit between initial presentation or diagnosis and entry into the
Registry. Patient and/or parental consentmust be obtained prior
to case registration, with the level of consent tiered according to
the extent to which the information may be shared (own center,
own country, EUmember states, international). The I-DSDReg-
istry is approved by the National Research Ethics Service of the
United Kingdom.
The terminology used within the Registry is based on the
nomenclature initially developed at theChicago consensusmeet-
ing and which has continued to evolve subsequently (9, 15). In
addition to details of diagnosis, the I-DSD Registry collects sim-
ple information on physical conditions which affect systems
other than the reproductive system, as well as the occurrence of
conditions such as small-for-gestational-age, and short stature.
See supplementary Table S1 – S4 for details of the data fields in
the Registry.
At the time of the study in September 2012, there were 1050
cases submitted by registered clinicians from 20 centers in 14
different countries. Reporting clinicians for cases represented a
range of specialties including pediatric endocrinology, adult en-
docrinology, clinical genetics and biochemistry and their coun-
tries of origin are outlined in supplementary Table S5. On ana-
lyzing the extracted data, 649 (62%) cases had a sufficient level
of consent to allow sharing of suitable information.Anonymized
data were obtained from the Registry regarding diagnosis,
karyotype, sex of rearing, clinical center, genetic investigations
and any associated anomalies. Until September 2012, the field
which captures ‘associated conditions’was labeled as ‘associated
malformations’. The field does not seek any further information
on whether the associated condition is early onset, late onset or
acquired. Short stature in congenital adrenal hyperplasia was
excluded from the analysis as this is a condition that is acquired
as a consequence of the management of the disorder. Further-
more, the data were subanalyzed with exclusion of cases where
the condition was known to be associated with specific anom-
alies, namely P450 Oxidoreductase deficiency (PORD), Mülle-
rianduct aplasia,Renal dysplasia andCervical Somite anomalies
(MURCS), Mayer-Rokitansky-Kuster-Hauser Syndrome
(MRKH), Turner Syndrome and 45,X/46,XY. Where informa-
tion was unclear or incomplete the reporting clinician was con-
tacted to obtain further information.
Results
Karyotype
Of the 649 cases analyzed, 460 (71%), were 46,XY,
121 (19%) were 46,XX, 42 (6%) were 45,X/46,XY, 8
(1%) were 45,X, 6 (1%) were 46,XX/46,XY, 2 (0.3%)
were 47,XXY, with other atypical karyotypes (such as
translocations) making up the remaining 10 cases (1%).
Of these cases with the respective karyotypes, associated
conditions were reported in 6 cases of 45,X (75%), 19
cases of 45,X/46,XY (45%), 112 cases of 46,XY DSD
(24%), 27 cases of 46,XXDSD(22%)and4 caseswith the
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atypical karyotypes (22%). Disorders of gonadal devel-
opment occur in patientswith a variety of karyotypes, and
in the current cohort, of the 63 cases of a disorder of
gonadal development with an associated condition, 33
(52%) were 46,XY, 3 (5%) were 46,XX, 5 (8%) were
45,X, 19 (30%) were 45,X/46,XY, 1 (2%) was 47,XXY,
and 2 (2%) had an atypical karyotype.
Multiple conditions
Of the 649 cases, associated conditions occurred in 168
(26%). Of these 168 cases, 103 (61%) cases had one con-
dition each, 31 (18%) had two conditions, 20 (12%) had
three and 14 (8%) had four or more with the maximum
number being eight. Multiple conditions (more than one
per case) were reported in 3 of 6 (50%) cases of 46,XX
disorders ofMüllerian development, 22 of 44 (50%) cases
of nonspecific 46,XY DSD, 25 of 63 (40%) cases of dis-
orders of gonadal development, 7 of 19 (37%) cases of
disorders of androgen action, 3 of 11 (27%) cases of dis-
orders of androgen excess and 2 of 18 (11%) cases of
disorders of androgen synthesis. Further details of the con-
ditions encountered are outlined in Table 1.
Range Of Conditions
The range anddistributionof associated conditions dif-
fered substantially between cases of 46,XY and 46,XX
DSD (Figure 1). Small-for-gestational age (SGA) was re-
ported in 26 of 112 cases (23%) of 46,XY DSD with as-
sociated conditions; however, there were no cases of SGA
in the 46,XX DSD group. CNS and cardiac conditions
were next most frequent in 46,XY DSD, each reported in
22 of the 112 cases (20%) of 46XY DSD with associated
conditions.
In the 90 cases of nonspecific XY DSD without any
clear diagnosis on the registry, 17 (19%) were reported to
be SGA, 11 (12%) had cardiac abnormalities and 8 (9%)
had involvement of the central nervous system (CNS) (Ta-
ble 1). In the 153 cases of disorders of gonadal develop-
ment on the registry, 19 (12%) had short stature (15 of
which occurred in cases with 45,X or 45,X/46,XY karyo-
type, 3 in cases of 46,XYDSD and 1 case with an atypical
karyotype), 17 (11%) had renal anomalies (7 of which
occurred in cases with 45,X or 45,X/46,XY karyotype)
and 14 (9%) had cardiac abnormalities (6 of which oc-
curred in cases with 45,X or 45,X/46,XY karyotype) (Ta-
ble 1).
Conditions affecting the skeleton were present in 12 of
27 (44%) cases of 46,XX DSD with an associated condi-
tion and these cases included 2 cases of MURCS, diag-
nosed clinically, 7 cases of PORD all with genetic confir-
mation of diagnosis, 2 unconfirmed nonclassical 3-
hydroxysteroid dehydrogenase deficiency, and 1 case of
11-hydroxylase deficiency, with genetic confirmation.
Conditions involving renal development were encoun-
tered in 8 of the 27 cases (30%) and were commonest in
Table 1. Reported anomalies according to disorder classification. SGA: Small for gestational age, CNS: Central
nervous system, GI: Gastrointestinal, ENT: Ear, nose and throat, PMDS: Persistent Müllerian Duct Syndrome
Number of cases with each type of anomaly
Disorder
Type
(number of
accessible
cases in
Registry)
Number
of cases
with
anomaly
Adrenal Blood
&
Lymph
CNS Craniofacial ENT Eyes GI
Tract
Heart Renal Respiratory SGA Short
Stature
Skeletal Skin Undefined
syndrome
Other Number of
cases with
anomaly by
karyotype
Gonadal
Development
(153)
63 1 3 9 9 7 4 4 14 17 4 5 19 7 - 3 6 46,XY - 33
46,XX - 3
45,X - 5
45,X/46,XY
- 19
47,XXY - 1
Other - 2
Androgen
Synthesis
(100)
18 - - 1 1 - - - - - - 1 - 13 1 - 3 46,XY - 9
46,XX - 9
Androgen
Action (172)
19 - - 3 1 - 2 2 3 3 2 5 4 3 1 1 7 46,XY - 19
Androgen
Excess (75)
9 - - 1 1 - - 1 1 2 - - - 1 - 1 5 46,XY - 1
46,XX - 8
Non-specific
XY DSD
(90)
44 1 1 8 4 5 3 6 11 7 3 17 4 5 3 1 10 46,XY - 44
XX
Müllerian
Devpt (12)
6 - - 1 - - 1 - 1 6 - - - 2 - 1 - 46,XX - 6
PMDS (5) 1 - - - - - - - - - - - - - - - 1 46,XY - 1
Leydig Cell
Defects (17)
1 - - 1 1 - 1 - - - - - - 1 1 - - 46,XY - 1
Other (25) 7 1 - 3 - - - - 2 - - - 1 - - 1 1 46,XY - 5
46,XX - 1
45,X - 1
TOTAL
(649)
168 3 4 27 17 12 11 13 32 35 9 28 28 32 6 8 33
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those with a 46,XX disorder of Müllerian development,
occurring in 6 of 12 cases in the Registry (50%), and pres-
ent in all such cases which had an anomaly recorded.
As associated conditions are already known to occur in
some syndromes associated with DSD, 8 cases of Turner
syndrome, 42 cases of 45,X/46,XY,19 cases of PORDand
12 cases of Mullerian development anomalies were ex-
cluded from the overall 649 cases. Of the remaining 568
cases, 127 (22%) had an associated condition that did not
form a recognized part of the disorder. Of these 127, 108
(85%) were 46,XY, 15 (12%) were 46,XX, 2 (2%) had a
nonsex chromosome rearrangement, and there was 1 case
each (1%)of 46,XX/46,XYand47,XXY, respectively.Of
these 127 cases, 75 (60%) had one condition, 22 (17%)
had two, 18 (14%) had 3 and 12 (9%) had 4 ormore,with
the maximum number of conditions encountered in one
patient being8.Among these127cases therewere44 cases
of nonspecific 46,XY DSD, 39 cases of disorders of go-
nadal development, 19 cases of disorders of androgen ac-
tion, 10 case of disorders of androgen synthesis, 9 cases of
disorders of androgen excess, 1 case each of Leydig cell
defects and persistent Müllerian duct syndrome, and 6
cases classified as ‘other’ disorders. Of the 39 cases of
disorders of gonadal development 10 (26%) had a renal
condition, 8 (21%) had a cardiac condition, 8 (21%) had
a CNS condition, 8 (21%) had a craniofacial disorder, 4
each (10%) had short stature, ENT, GI tract, respiratory
or skeletal conditions, 3 (8%) had blood and lymph con-
ditions, eye conditions, SGAor an unidentified syndrome,
and 1 (3%) had an adrenal condition.
The pattern and frequency of anomalies also varied
between 46,XY and 46,XX DSD after exclusion of the
syndromic DSD conditions (Figure 2). Of the 451 cases of
46,XYDSD, an associated condition was reported in 108
(24%) and in 15 of 98 cases (15%) of 46,XX DSD. In
46,XY DSD, SGA was the most frequent condition in 26
cases (24%), with cardiac anomalies in 22 cases (20%)
and CNS conditions in 21 cases (19%). In 46,XX DSD,
there was an even spread of conditions with the most fre-
quent condition being skeletal occurring in 3 of 15 cases
(20%).
Monogenic DSD
Of 170 cases reported as Androgen Insensitivity Syn-
drome (AIS), 19 (11%) were recorded as having an asso-
ciated condition. Of these 19 cases, 9 had a confirmed
androgen receptor (AR) mutation, occurring in 6 cases of
Complete AIS and 3 cases of Partial AIS. Associated con-
ditions were reported to affect the renal system in 2 cases,
skeleton in 1, skin in 1, CNS in 1, GI tract in 1, heart in 1
and an unspecified condition in 5 cases (Table 2). Asso-
ciated conditionswere also reported in8of72 (11%)cases
of 21-hydroxylase deficiency (1 of which had confirmed
CYP21A2mutation, while the remainder were diagnosed
clinically), 4 of 26 (15%) cases of 17-hydroxysteroid
dehydrogenase type 3 deficiency (all with confirmed
HSD17B3 mutation), and 2 of 19 cases (10%) of 5-re-
ductase type 2 deficiency. In the 8 cases of 21-hydroxy-
lase deficiency, two had renal conditions. In the remain-
der, there was one case of a CNS condition, one affecting
the GI tract and one case each detailed as severe autism,
spastic paraplegia, polyarthritis, learning disability and
one not specified.
Discussion
The results from this analysis of the I-DSDRegistry reveal
that associated conditions are frequent inDSD,with a rate
of 27%, which is over 10 times the birth prevalence of
congenital anomalies (17). This is not unexpected, given
that the presence of one congenital condition is known to
be associated with the presence of further anomalies as
Figure 1. Range of anomalies reported in 46,XX and 46,XY
DSD SGA: Small for gestational age, CNS: Central nervous
system, GI: Gastrointestinal, ENT: Ear, nose and throat
Figure 2. Range of anomalies reported after exclusion of
known DSD syndromic associations in 46,XX and 46,XY
DSD SGA: Small for gestational age, CNS: Central nervous
system, GI: Gastrointestinal, ENT: Ear, nose and throat
4 Associated conditions in DSD J Clin Endocrinol Metab
The Endocrine Society. Downloaded from press.endocrine.org by [${individualUser.displayName}] on 04 February 2014. at 02:46 For personal use only. No other uses without permission. . All rights reserved.
disrupting factors, whether environmental or genetic, are
likely to affectmultiple developmental processes. Further-
more, approximately 10% of the cases of DSD had more
than one associated condition, highlighting the need for
input frommultiple specialists.When caseswithDSD syn-
dromes and chromosomal anomalies were excluded, the
overall frequency of associated conditions was similar to
the overall cohort. These figures are also in keeping with
the findings of an epidemiological study carried out in
Germany which identified a higher rate of 37.5% for as-
sociated malformations in infants with ambiguous geni-
talia (18).
Although the ranges of anomalies that are encountered
are different, it is of interest that in the current cohort of
cases in the I-DSD Registry, the reported prevalence of
associated conditions in 46,XY and 46,XX DSD at 24%
and 22%was similar. With the exclusion of the cases that
are well known to be associated with anomalies, the prev-
alence of associated conditions in the other cases of 46,XY
and 46,XX DSD was 24% and 15%, respectively. The
type of conditions encountered in 45,X/46,XY cases bears
a striking resemblance to the known phenotype in Turner
syndrome, with partial or complete gonadal dysgenesis.
This is reflected in the high frequency of associated con-
ditions in all cases with gonadal dysgenesis. Our findings
echo the description of the 45,X/46,XY phenotype by
Tosson et aland Telvi et al (19, 20) and the cardiac phe-
notype refined by De Groote et al (21). These findings
highlight the importance of thorough screening for asso-
ciated conditions in bothmale and female individualswith
this karyotype.
It has long been recognized that there is a strong asso-
ciation between SGA and DSD (1, 22), and this was re-
flected in our findings. It was notable that there were no
reported cases of SGA in 46,XX DSD. It has been specu-
lated that altered prenatal androgen exposuremay alter in
utero growth but this is debatable (23, 24). An alternative
hypothesis for the origins of low birthweight in 46,XY
DSD is that both are the result of early placental insuffi-
ciency (25, 26) and this requires further investigation.
Table 2. Reported anomalies in monogenic conditions. SGA: Small for gestational age, CNS: Central nervous
system, GI: Gastrointestinal, ENT: Ear, nose and throat. Two cases reported as possible non-classic 3-HSD have been
included in Table 1 as androgen synthesis disorders, but due to diagnostic uncertainty have not been included in the
monogenic conditions in Table 2. Two cases described as “disorders of androgen excess” have the diagnosis “other”
with no confirmed diagnosis and are therefore not included in Table 2
Number of cases with each anomaly
Disorder Total
number
Number
cases
with
anomaly
CNS Craniofacial Eyes GI
Tract
Heart Renal Respiratory SGA Short
Stature
Skeletal Skin Undefined
syndrome
Other
Disorders of
androgen
synthesis
17
hydroxysteroid
dehydrogenase
type 3
deficiency
26 4 1 - - - - - - - - 1 - - 3
5
reductase type 2
deficiency
19 2 - - - - - - - 1 - - 1 - -
P450
oxidoreductase
deficiency
19 10 - 1 - - - - - - - 10 - - -
Disorder of
Androgen
Action
Complete
Androgen
Insensitivity
Syndrome (AR
mutation ve)
77 6 1 - - 1 1 1 - - - - 1 - 3
Complete
Androgen
Insensitivity
Syndrome (AR
mutation --ve /
unknown)
16 3 - - - - - 1 - - - 1 - - 1
Partial
Androgen
Insensitivity
Syndrome (AR
mutation ve)
39 3 - - - - - 1 - - - 1 - - 2
Partial
Androgen
Insensitivity
Syndrome (AR
mutation -ve)
38 7 2 1 2 1 2 - 2 5 4 1 - 1 1
Disorder of
Androgen
Excess
21
hydroxylase
deficiency
72 8 1 - - 1 1 2 - - - - - - 5
11
hydroxysteroid
dehydrogenase
deficiency
1 1 - 1 - - - - - - - 1 - 1 -
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In 46,XX DSD, an association with skeletal and renal
anomalies is recognized in conditions such as MURCS
(Müllerian duct aplasia, Renal dysplasia and Cervical
Somite anomalies), Mayer-Rokitansky-Kuster-Hauser
Syndrome (MRKH), and P450 oxidoreductase deficiency
(PORD) (7, 27). This was borne out by our results, in
which renal conditions were common in women with
46,XX DSD and disorders of Müllerian development.
Similarly, skeletal involvement was also observed in
women with 46,XX DSD and PORD or MURCS. Renal
disorders are also a recognized feature of 46,XYDSD due
to the Denys Drash and WAGR (Wilms, Aniridia, Geni-
tourinary anomalies, mental Retardation) syndromes.
Furthermore, bone and kidney abnormalities combined
with genital anomalies are a component of Smith Lemli
Opitz syndrome (28). Renal tract anomalies have previ-
ouslybeen reportedasoccurring in14of66 females (21%)
with congenital adrenal hyperplasia (29), and were also
confirmed to be present in the current cohort occurring in
2 cases of 21-hydroxylase deficiency. When recognized
associations were excluded from the analysis, renal and
skeletal disorders were still encountered in up to 4% of
cases of 46,XX DSD and 46,XY DSD.
The unexpected presence of renal abnormalities in AIS
cases with a confirmed androgen receptor mutation raises
a question about the developmental role of the androgen
receptor in the kidney. Previously, an association between
CAIS and renal anomalies has been described in one case
(30). In mice, the kidney is one of the most androgen sen-
sitive, nonreproductive organs, with a close correlation
between kidneymass and androgen levels in themale (31).
In addition, several developmental genes are known to be
androgen-regulated in the mouse (32). Our finding of 2
cases with renal anomalies in congenital adrenal hyper-
plasia (CAH) is also worthy of emphasis, as it highlights
the importance of thorough investigation of the whole
renal tract in suchpatients.Ten cases reportedasAISwith-
out a confirmedARmutationhadanassociated condition.
Of these, 5 cases had SGA and 4 had short stature. Given
that these associations are often encountered in cases of
gonadal dysgenesis, these cases of presumed AIS need a
thorough investigation of gonadal function.
It is possible that some of the associations revealed by
our analysis of the Registry may represent co-occurrence
of anomalies by chance. Renal tract anomalies have been
reported as occurring with a frequency of 25 per 1,000 in
the general European population (17). This compares to a
frequency in our analysis of 35/649, equivalent to 54 per
1000. The frequency of cardiac anomalies, the second
most common anomaly in our population, is reported as
8 per 1,000 in the European population (33). This com-
pares to the occurrence of cardiac anomalies in our anal-
ysis of 32/649, equivalent to 49 per 1,000.
The I-DSD Registry is not an epidemiological registry
and as it does not collect information on all cases of DSD,
it may suffer from a reporting and selection bias. It is
recognized that there may be a bias towards the reporting
of more clinically unusual cases, which could increase the
reported prevalence of anomalies. Registry users can also
choose the extent of data sharingwith other users for each
individual case and this sharing may depend on the pa-
tient’s or clinician’s preference. Basedon the access level of
the investigators, only 60% of the cases in the Registry
could be accessed for this study and this may have also
introduced some selection bias. However, the similarities
between our results and the findings of a national study
suggest that the prevalence figure of 25% for associated
conditions probably is representative of the true preva-
lence (18). In particular, cases of CAH may be under-
represented in the Registry due to reporting methods,
given that the incidence in the general population is esti-
mated at around1 in15,000 live births (34). The incidence
of AIS was described in a Danish population registry as 1
in 20,400 (35), while MRKH is estimated as occurring in
1 in 4,500 females (36). However the Registry does not
necessarily represent the population prevalence of these
disorders as it relies on clinician reporting rather that pop-
ulation screening.
All data are self-recorded by the clinician, with little
recourse to source verification of entered data and it can
be difficult in such a registry to be clear that all users have
the same understanding of an associated condition that is
congenital. It is also possible that some congenital condi-
tions may not be manifested until a later age. Until re-
cently, the data collection form asked investigators to en-
ter data on ‘associated malformations’ which implies
congenital conditions. More recently, the term ‘malfor-
mations’ has been replaced by the term ‘conditions’. It
would be beneficial in future revisions of the Registry to
provide some explanatory data to ensure that conditions
that are considered to be of congenital and those consid-
ered to be acquired are captured separately and there may
be additional value in assessing the age of onset of the
manifestation of the condition.
However, the use of an international registry of such
rare conditions in such a large group of cases has, never-
theless, pointed to some new associations in DSD and the
study highlights the strength of a global effort to collect
data in rare diseases which will encourage reporting of
more cases of DSD with associated conditions. In conclu-
sion,wehave found that, in this cohort of cases, associated
anomalies are reported in around a quarter of cases of
DSD. The prevalence of associated conditions is much
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greater in disorders of gonadal development and nonspe-
cific 46,XYDSD. In46,XYDSD, the largest groupof cases
in the Registry, commonest associated conditions in-
cluded SGA, cardiac and CNS. In many cases of DSD the
etiology remains obscure and the current findings may
lead to new research targets as well as improved care of
those affected by these disorders.
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